sun pharma received usfda import alert karkhadi unit gujarat shares company tanked nearly 6 percent thursday speaking cnbctv18 regarding impact ban anmol ganjoo vp institutional equities jm financial says since revenue contribution gujarat unit 12 percent company unlikely suffer financially
however softer issues may possibly drag management bandwidth first time company received import alert ganjoo adds
anmol interview ekta batra anuj cnbctv18
anuj material news think stock deserves punishment apart 4 percent fall seen today
two clear aspects happened respect import alerts sun pharmaceutical industries one direct financial impact count extremely worried revenue contribution plant 12 percent overall sun pharma sales terms financial impact directly correlated plant question material
however import alert fairly significant far impact softer issues company concerned sun pharma never received import alert problem caraco got resolved period time therefore netnet financial impact directly correlated facility question meaningful multiple could pressure clarity resolution emerges far particular plant regulatory issue concerned
ekta softer issues worried sun pharma would want clarity management received red flag plant communication front
think worried aspects look escalation ladder timeline associated standard protocols respect far 483 issues disclosure market concerned think recent development followed companies given sun pharmas track record think obligation report communicate 483
however meant softer issue saw issue caraco took lot management bandwidth also see time specifically sun pharma times collateral damage far sales concerned remediation cost given also api produced facility although cephalosporin meaningful filings get delayed side direct revenue contribution plant issues terms drag development management bandwidth focus forth
respect sun pharmas valuation multiple also amount comfort company top quality issues best class company confidence extent gets shaken whenever development like
ekta think market also factoring fact usfda highly vigilant indian companies past maybe amount slack cutting sun pharma incremental increase vigilance seen us fda front
anecdotal indicator suggest us fda activism vigilance increased many folds last sixten months see actions across companies followup 483 extrapolate amount witchhunt specific companies targets think would stretching far also bear mind far volume penetration indian pharma generic companies us concerned also gone many folds greater vigilance fairly consistent increase volume
